Argonaut Gold (AR.TO)

Overall impact
B (66)

Commentary

Argonaut Gold is a strong overall performer. With a 'B' rating of 66.4 for overall impact (76th percentile compared to all companies), Argonaut Gold ranks 327th out of 585 industry peers, behind Biogen, Ionis Pharmaceuticals, Gilead Sciences and 323 others, and ahead of Grifols, Jazz Pharmaceuticals, Bluebird Bio and 255 others. On top material causes for Argonaut Gold's industry (Pharmaceuticals & Biotech), Argonaut Gold performs well in Child and Maternal Health (81.0 score), Access to Affordable Healthcare (87.1), Improved Mental Health (87.3) and 3 other causes where it received an 'A' score and performs poorly in Reduced Waste (33.8 score) and Disaster Readiness and Effective Aid (31.5).
Impact
Cause AR.TO
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
On, Canada
Share classes
AR.TO
Description
Argonaut Gold Inc. engages in the production and sale of gold, as well as mine development and exploration businesses in North America. It also explores for silver. The company's flagship property is the 100% owned Magino mine property, which comprises seven patented mining claims, four leased mining claims, and 69 unpatented mining claims totaling 2,204.495 hectares located in Ontario, Canada. Additionally, Argonaut Gold Inc. provides management services. Founded in 2009, the company is based in Toronto, Canada. As of July 12, 2024, Argonaut Gold Inc. operates as a subsidiary of Alamos Gold Inc.
Material causes
Ethos considers the following causes material for Argonaut Gold, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.